Australia markets closed

Antisense Therapeutics Limited (ANP.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.0600+0.0030 (+5.26%)
At close: 04:10PM AEDT
Currency in AUD

Valuation measures4

Market cap (intra-day) 54.09M
Enterprise value 43.27M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)5.42
Enterprise value/revenue N/A
Enterprise value/EBITDA -3.27

Trading information

Stock price history

Beta (5Y monthly) 1.23
52-week change 3-30.23%
S&P500 52-week change 314.90%
52-week high 30.1100
52-week low 30.0500
50-day moving average 30.0627
200-day moving average 30.0689

Share statistics

Avg vol (3-month) 3443.01k
Avg vol (10-day) 3204.46k
Shares outstanding 5901.55M
Implied shares outstanding 6949M
Float 8601.19M
% held by insiders 116.27%
% held by institutions 13.95%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:10
Last split date 306 Nov 2013

Financial highlights

Fiscal year

Fiscal year ends 30 June 2023
Most-recent quarter (mrq)30 June 2023


Profit margin 0.00%
Operating margin (ttm)-598.13%

Management effectiveness

Return on assets (ttm)-41.69%
Return on equity (ttm)-73.14%

Income statement

Revenue (ttm)1.58M
Revenue per share (ttm)0.00
Quarterly revenue growth (yoy)-28.40%
Gross profit (ttm)1.55M
EBITDA -11.75M
Net income avi to common (ttm)-11.38M
Diluted EPS (ttm)-0.0200
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)10.97M
Total cash per share (mrq)0.01
Total debt (mrq)142.1k
Total debt/equity (mrq)1.42%
Current ratio (mrq)4.51
Book value per share (mrq)0.01

Cash flow statement

Operating cash flow (ttm)-8.15M
Levered free cash flow (ttm)-4.17M